{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:33:49Z","timestamp":1789947229482,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T00:00:00Z","timestamp":1496707200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00277-017-3040-8","type":"journal-article","created":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T23:10:06Z","timestamp":1496704206000},"page":"1297-1302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden"],"prefix":"10.1007","volume":"96","author":[{"given":"Irene","family":"Bertozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Bogoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Biagetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Duner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luigia","family":"Randi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,6]]},"reference":[{"key":"3040_CR1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3322\/caac.20009","volume":"59","author":"AM Vannucchi","year":"2009","unstructured":"Vannucchi AM, Guglielmelli P, Tefferi A (2009) Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 59:171\u2013191","journal-title":"CA Cancer J Clin"},{"key":"3040_CR2","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224\u20132232","journal-title":"J Clin Oncol"},{"key":"3040_CR3","first-page":"73","volume":"23","author":"PJ Genderen Van","year":"1994","unstructured":"Van Genderen PJ, Michiels JJ (1994) Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Med 23:73\u201377","journal-title":"Presse Med"},{"key":"3040_CR4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","volume":"26","author":"G Finazzi","year":"2012","unstructured":"Finazzi G, Carobbio A, Thiele J et al (2012) Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 26:716\u2013719","journal-title":"Leukemia"},{"key":"3040_CR5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.blre.2010.08.002","volume":"24","author":"E Papadakis","year":"2010","unstructured":"Papadakis E, Hoffman R, Brenner B (2010) Thrombohemorrhagic complications of myeloproliferative disorders. Blood rev 24:227\u2013232","journal-title":"Blood rev"},{"key":"3040_CR6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF01707281","volume":"63","author":"A Wehmeier","year":"1991","unstructured":"Wehmeier A, Daum I, Jamin H et al (1991) Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. a retrospective analysis of 260 patients. Ann Hematol 63:101\u2013106","journal-title":"Ann Hematol"},{"key":"3040_CR7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","volume":"131","author":"AP Wolanskyj","year":"2005","unstructured":"Wolanskyj AP, Lasho TL, Schwager SM et al (2005) JAK2V617F mutation in essential thrombocythemia: clinical associations and long-term prognostic relevance. Br J Haematol 131:208\u2013213","journal-title":"Br J Haematol"},{"key":"3040_CR8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","volume":"116","author":"A Alvarez-Larran","year":"2010","unstructured":"Alvarez-Larran A, Cervantes F, Pereira A et al (2010) Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 116:1205\u20131210","journal-title":"Blood"},{"key":"3040_CR9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","volume":"93","author":"V Stefano De","year":"2008","unstructured":"De Stefano V, Za T, Rossi E et al (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93:372\u2013380","journal-title":"Haematologica"},{"key":"3040_CR10","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054\u20131061","journal-title":"Lancet"},{"key":"3040_CR11","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J med 352:1779\u20131790","journal-title":"N Engl J med"},{"key":"3040_CR12","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405","journal-title":"Blood"},{"key":"3040_CR13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","volume":"110","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P et al (2007) Clinical profile of homozygous Jak2617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110:840\u2013846","journal-title":"Blood"},{"key":"3040_CR14","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","volume":"19","author":"E Antonioli","year":"2005","unstructured":"Antonioli E, Guglielmelli P, Pancrazzi A et al (2005) Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19:1847\u20131849","journal-title":"Leukemia"},{"key":"3040_CR15","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G et al (2005) Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on Jak2 mutation status: a prospective study. Lancet 366:1945\u20131953","journal-title":"Lancet"},{"key":"3040_CR16","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","volume":"24","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Rumi E, Pietra D et al (2010) A prospective study of 338 patients with polycythemia vera: the impact of JAK2(V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 24:1574\u20131579","journal-title":"Leukemia"},{"key":"3040_CR17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.11653","volume":"93","author":"E Antonioli","year":"2008","unstructured":"Antonioli E, Guglielmelli P, Poli G et al (2008) Influence of JAK2V617 allele burden on phenotype in essential thrombocythemia. Haematologica 93:41\u201348","journal-title":"Haematologica"},{"key":"3040_CR18","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692\u2013694","journal-title":"J Thromb Haemost"},{"key":"3040_CR19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.beha.2005.07.004","volume":"19","author":"CN Harrison","year":"2006","unstructured":"Harrison CN, Green AR (2006) Essential thrombocythaemia. Best Pract res Clin Haematol 19:439\u2013453","journal-title":"Best Pract res Clin Haematol"},{"key":"3040_CR20","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224\u20133222","journal-title":"J Clin Oncol"},{"key":"3040_CR21","first-page":"29","volume":"142","author":"A Tefferi","year":"2008","unstructured":"Tefferi A (2008) Primary myelofibrosis. Cancer Treat res 142:29\u201349","journal-title":"Cancer Treat res"},{"key":"3040_CR22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J med 353:33\u201345","journal-title":"N Engl J med"},{"key":"3040_CR23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","volume":"109","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Niblack J, Wadleigh M et al (2007) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer 109:68\u201376","journal-title":"Cancer"},{"key":"3040_CR24","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","volume":"355","author":"PJ Campbell","year":"2006","unstructured":"Campbell PJ, Green AR (2006) The myeloproliferative disorders. N Engl J med 355:2452\u20132466","journal-title":"N Engl J med"},{"key":"3040_CR25","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","volume":"110","author":"G Barosi","year":"2007","unstructured":"Barosi G, Bergamaschi G, Marchetti M et al (2007) JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110:4030\u20134036","journal-title":"Blood"},{"key":"3040_CR26","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","volume":"22","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P et al (2008) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22:1299\u20131307","journal-title":"Leukemia"},{"key":"3040_CR27","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","volume":"110","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P et al (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110:840\u2013846","journal-title":"Blood"},{"key":"3040_CR28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","volume":"106","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Lasho TL, Schwager SM et al (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 106:631\u2013635","journal-title":"Cancer"},{"key":"3040_CR29","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","volume":"21","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P et al (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21:1952\u20131959","journal-title":"Leukemia"},{"key":"3040_CR30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.thromres.2014.11.006","volume":"135","author":"M Borowczyk","year":"2015","unstructured":"Borowczyk M, Wotjtaszewska M, Lewandowski K et al (2015) The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Thromb res 135:272\u2013280","journal-title":"Thromb res"},{"key":"3040_CR31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s12185-015-1871-4","volume":"102","author":"EM Kander","year":"2015","unstructured":"Kander EM, Raza S, Zhou Z et al (2015) Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. Int J Hematol 102:587\u2013593","journal-title":"Int J Hematol"},{"key":"3040_CR32","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1182\/blood-2006-06-029769","volume":"109","author":"RE Gale","year":"2007","unstructured":"Gale RE, Allen AJ, Nash MJ et al (2007) Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years. Blood 109:1241\u20131243","journal-title":"Blood"},{"key":"3040_CR33","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3324\/haematol.13074","volume":"93","author":"A Theocharides","year":"2008","unstructured":"Theocharides A, Passweg JR, Medinger M et al (2008) The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica 93:1890\u20131893","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3040-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3040-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3040-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T02:29:19Z","timestamp":1498271359000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3040-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,6]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3040"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3040-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,6]]}}}